Text Size

Effect of Modified Fujita Technique Uvulopalatoplasty on Oxidative DNA Damage Levels in Patients With Obstructive Sleep Apnea SyndromE (OSAS)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Vural Fidan, Erzurum Regional Training & Research Hospital
ClinicalTrials.gov Identifier:
NCT01635699
First received: July 4, 2012
Last updated: July 6, 2012
Last verified: July 2012
History of Changes
  Purpose

The purpose of this study is to determine the possible effects of uvulopalatopharngoplasty (UPPP) -which is a a therapy used on patients with Obstructive sleep apnea syndrome (OSAS- on oxidative damage.


Condition
Sleep Apnea, Obstructive

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Effect of Modified Fujita Technique Uvulopalatoplasty on Oxidative DNA Damage Levels in Patients With Obstructive Sleep Apnea SyndromE

Resource links provided by NLM:

MedlinePlus related topics: Sleep Apnea
U.S. FDA Resources

Further study details as provided by Erzurum Regional Training & Research Hospital:

Biospecimen Retention:   Samples Without DNA

serum, whole blood


Enrollment: 49
Study Start Date: June 2008
Study Completion Date: March 2011
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Detailed Description:

Obstructive sleep apnea syndrome (OSAS) is a sydrome which has characteristic upper way obstruction and a decrease in blood oxygen saturation as sleeping. uvulopalatopharngoplasty (UPPP)is one of the surgical approaches applied to the patients with OSAS, since the oxidative damage markers have been found high in patients with OSAS. Although antioxidant levels were higher in patients with OSAS than those in normal population, there is report about the effect of UPPP on antioxidant status in patients with OSAS. We performed this study to confirm whether is there a We performed the present study to confirm whether there is a relationship between the OSAS and oxidative damage before and after UPPP.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Patients who underwent uvulopalatopharngoplasty (UPPP)for Obstructive sleep apnea syndrome (OSAS) at the otolaryngology department of our hospital in Erzurum, Turkey.

Criteria

Inclusion Criteria:

  • Patients who underwent uvulopalatopharngoplasty (UPPP)for Obstructive sleep apnea syndrome (OSAS)

Exclusion Criteria:

  • Anormal nasopharyngeal computed tomography, chronic diseases such as diabetes mellitus, hypertension etc.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01635699

Locations
Turkey
Erzurum Regional Educational Researh Hospital
Erzurum, Turkey, 25000
Sponsors and Collaborators
Erzurum Regional Training & Research Hospital
Investigators
Principal Investigator: vural fidan, operating surgeon doctor eskisehir yunus emre state hospital (still works here)
  More Information

No publications provided

Responsible Party: Vural Fidan, operating surgeon doctor, Erzurum Regional Training & Research Hospital
ClinicalTrials.gov Identifier: NCT01635699     History of Changes
Other Study ID Numbers: ATUNI-1
Study First Received: July 4, 2012
Last Updated: July 6, 2012
Health Authority: Turkey: Ministry of Health

Keywords provided by Erzurum Regional Training & Research Hospital:
DNA oxidation
obstructive sleep apnea
lipid peroxidation
oxidative stresses

Additional relevant MeSH terms:
Apnea
Sleep Apnea Syndromes
Sleep Apnea, Obstructive
Respiration Disorders
Respiratory Tract Diseases
Signs and Symptoms, Respiratory
 Signs and Symptoms
Sleep Disorders, Intrinsic
Dyssomnias
Sleep Disorders
Nervous System Diseases

ClinicalTrials.gov processed this record on May 16, 2013